← Leaderboards
Ernest Ramsay Camp
Medical University Of South Carolina
$1,801,421
Attributed
$2,735,601
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $642.8K · FY2010–25$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,735,601 · 2
VA$0 · 1
By mechanism
R01$1,868,361 · 1
K08$867,240 · 1
I01$0 · 1
Top collaborators
- Mark P Rubinstein3 shared
Most similar at Medical University Of South Carolina
Same institution · by research overlap
- Yusuf Awni Hannun$36,962,745
- Lina M Obeid$14,979,081
- Besim Ogretmen$19,638,711
- Cungui Mao$8,632,959
- Shikhar Mehrotra$11,720,155
Others in their field
Top investigators on “Cessation Of Life”
- David R. Weir · University Of Michigan At Ann Arbor$345,522,974
- John M Lachin · George Washington University$134,302,892
- David M Nathan · Massachusetts Institute Of Technology$127,791,564
- Judith S Hochman · New York University School Of Medicine$112,898,313
- Jeffrey H Samet · Boston University Medical Campus$91,739,367
- Judith S. Currier · University Of California Los Angeles$85,330,415
Research focus
Cessation Of LifeMalignant NeoplasmsClinically RelevantMediatingProgramsTumorDesignResponseMolecularNovel StrategiesGenerationsIn VivoOperative Surgical ProceduresMediator Of Activation ProteinClinical TrialsLoss Of FunctionEffectivenessPathway InteractionsGenesMultidisciplinaryMouse ModelCancer EtiologyFoundationsFluorouracil
Grant awards (12)
Defining the role of tumoral MHC Class I Expression in Mediating Colorectal Cancer Racial Disparities$628,469
R01 · FY2025 · CA
Defining the role of tumoral MHC Class I Expression in Mediating Colorectal Cancer Racial Disparities$597,046
R01 · FY2024 · CA
Defining the role of tumoral MHC Class I Expression in Mediating Colorectal Cancer Racial Disparities$642,846
R01 · FY2023 · CA
Targeting Sphinogsine-1-phosphate to overcome SNAI1-mediated therapy resistance in rectal cancer$0
I01 · FY2022 · VA · contact PI
Targeting Sphinogsine-1-phosphate to overcome SNAI1-mediated therapy resistance in rectal cancer$0
I01 · FY2021 · VA · contact PI
Targeting Sphinogsine-1-phosphate to overcome SNAI1-mediated therapy resistance in rectal cancer$0
I01 · FY2020 · VA · contact PI
Targeting Sphinogsine-1-phosphate to overcome SNAI1-mediated therapy resistance in rectal cancer$0
I01 · FY2019 · VA · contact PI
Innovative Delivery Strategy for CaSm Gene Therapy in Pancreatic Cancer$173,448
K08 · FY2014 · CA · contact PI
Innovative Delivery Strategy for CaSm Gene Therapy in Pancreatic Cancer$173,448
K08 · FY2013 · CA · contact PI
Innovative Delivery Strategy for CaSm Gene Therapy in Pancreatic Cancer$173,448
K08 · FY2012 · CA · contact PI
Innovative Delivery Strategy for CaSm Gene Therapy in Pancreatic Cancer$173,448
K08 · FY2011 · CA · contact PI
Innovative Delivery Strategy for CaSm Gene Therapy in Pancreatic Cancer$173,448
K08 · FY2010 · CA · contact PI